Keeping an Eye on Parexel International
TraderMark
•
Tue, Apr 15, 2008
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
370 people get PRXL articles and Market Currents by email alert.
Get email alerts on PRXL »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Parexel: Put on the RadarTate Dwinnell • Thu, Jan 10, 2008 -
To learn more about Seeking Alpha Pro, click here.
-
-
Strengthening Moats Mean Improving Returns For CRO InvestorsMorningstar • Mon, Dec 31, 2012 -
-
-
Update: 8 High-Growth Healthcare Stocks With Strong Sources Of ProfitabilityKapitall • Tue, Jul 17, 2012 -
8 Undervalued Healthcare Stocks With Strong Receivable TrendsKapitall • Thu, Jun 21, 2012
-
8 High-Growth Healthcare Stocks With Strong Sources Of ProfitabilityKapitall • Tue, Jun 12, 2012
-
Sector Detector: Strong Earnings Balance Global WorriesScott Martindale • Thu, May 3, 2012 -
-
16 Rallying Healthcare Stocks Being Sold By Hedge FundsKapitall • Tue, Feb 21, 2012
-
Contract Research Organizations Still On Sale As Industry ReboundsMorningstar • Thu, Jan 12, 2012
-
Leading CROs Will Gain From Drug Research ReboundMorningstar • Mon, Oct 3, 2011
-
-
-
-
-
-
-
-
CRO Investment Opportunities Remain CompellingMorningstar • Thu, Nov 11, 2010
-
PR Newswire (Mon, 6:00AM)
-
PR Newswire (Thu, 4:05PM)
-
PR Newswire (Jun 11, 2013)
-
PR Newswire (May 23, 2013)
-
at CNBC.com (May 13, 2013)
-
PR Newswire (Apr 30, 2013)
-
PR Newswire (Apr 30, 2013)
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 2, 2013)
-
PR Newswire (Feb 20, 2013)
-
PR Newswire (Jan 29, 2013)
-
PR Newswire (Jan 22, 2013)
-
PR Newswire (Jan 10, 2013)
-
PR Newswire (Jan 4, 2013)
-
PR Newswire (Jan 3, 2013)
-
PR Newswire (Dec 27, 2012)
PRXL vs. ETF Alternatives
Company Description
Currently, there's no company description for PRXL.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 21, 3:22 PM Parexel (PRXL -0.4%) slips on a tepid Neutral initiation at ISI today. The firm says that despite the potential tailwinds, current valuation is already reflective of the market's enthusiasm for the stock, and most of the near term good news has already been baked-in. Comment! [Healthcare]
- Tuesday, April 30, 5:13 PM PAREXEL (PRXL): Q1 EPS of $0.50 beats by $0.10. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, March 14, 4:15 PM Parexel (PRXL) accelerates its buyback program by adding an additional $50M in a new ASR agreement, bringing both programs to a total of $100M. Both plans are with JP Morgan Securities. Comment! [Healthcare]
- Tuesday, January 29, 5:55 PM More on Parexel (PRXL): FQ2 beats across the board on a 26% jump in total revenue. Net earnings climbed 65% on higher demand for its clinical R&D services and data analysis. Service revenue rose 27% to $422.1M, with newly-acquired Liquent contributing $400K in the quarter. Backlog at the end of December was approximately $4.54B, up 21.4% Y/Y. It also raises FY guidance, now expecting to earn $1.48 to $1.56 per share, with consolidated service revenue between $1.695B and $1.710B. Shares +3.4% AH. Comment! [Healthcare, Earnings]
- Tuesday, January 29, 4:06 PM PAREXEL (PRXL): FQ2 EPS of $0.41 beats by $0.08. Revenue of $422.1M (+26.7% Y/Y) beats by $2.32M. Shares -0.5% AH. (PR) Comment! [Earnings, Breaking News]
- Thursday, December 27, 2012, 2:09 PM Synergy Pharmaceuticals (SGYP +5.3%) moves up after saying its commenced Phase IIb clinical trials of plecanatide, a treatment for patients with constipation-predominant irritable bowel syndrome. The trial is being conducted at 70 sites in the U.S. and includes 350 patients. Parexel International (PRXL -2%) is the contract research organization for the trial. Comment! [Healthcare, On the Move]
- Thursday, December 27, 2012, 9:17 AM Parexel (PRXL +2.1%) acquires Liquent for $72M. The shares rose after the firm raised 2Q13 revenue guidance to $415M-$420M, GAAP EPS to be in range of $0.31-$0.34 and FY13 revenue of $1.67B-$1.69B and adj. EPS to be in range of $1.36-$1.43. The acquisition is expected to have dilutive impact of $0.02-$0.04 for FY13. (PR) Comment! [On the Move, Healthcare]
- Tuesday, October 30, 2012, 6:08 PM More on Parexel (PRXL) FQ1 EPS comes in-line but its top-line beats on a 25% jump in Y/Y revenue. For the current quarter, the company expects to report service revenue in the range of $400M to $410M and an EPS in the range of $0.31 to $0.33. For FY13, service revenue is expected to be in the range of $1.63B to $1.66B on earnings between $1.34 to $1.44. Comment! [Earnings]
- Tuesday, October 30, 2012, 5:56 PM Parexel International (PRXL): FQ1 EPS of $0.29 in-line. Revenue of $462.5M (+25.5% Y/Y) beats by $66M. (PR) Comment! [Earnings, Healthcare]
- Monday, September 17, 2012, 5:30 PM Parexel (PRXL) announces an Accelerated Share Repurchase agreement with JPMorgan to repurchase an aggregate of $50M of the company's common stock. The purchase is part of its existing $200M share repurchase program announced in August, and will conducted as part of a 10b5-1 trading plan that allows JPMorgan to make purchases on the company's behalf. Comment! [Healthcare]
- Wednesday, August 8, 2012, 6:58 PM PAREXEL International (PRXL): FQ4 EPS of $0.34 beats by $0.05. Revenue of $457.7M (+25.9% Y/Y) beats by $80M. (PR) Comment! [Earnings, Healthcare]
- Monday, April 30, 2012, 5:20 PM PAREXEL International (PRXL): FQ3 EPS of $0.33 beats by $0.02. Revenue of $356M (+18.1% Y/Y) beats by $6M. Shares -7% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Monday, January 30, 2012, 5:45 PM More on Parexel's FQ2: Though results were only in-line, the company is guiding for FQ3 revenue of $350M-$358M ($334.2M consensus) and EPS of $0.30-$0.32 ($0.23 consensus). In addition, it's guiding for FY12 (ends in June) revenue of $1.36B-$1.375B ($1.36B consensus) and EPS of $1.09-$1.17 ($1.11 consensus). PRXL now +10% AH. (PR) Comment! [Healthcare, Earnings, On the Move]
- Monday, January 30, 2012, 4:26 PM Parexel International (PRXL): FQ2 EPS of $0.23 in-line. Revenue of $333.2M (+9.5% Y/Y) in-line. Shares +0.7% AH. (PR) Comment! [Earnings, Healthcare]
- Wednesday, August 10, 2011, 3:56 PM Shares of Parexel (PRXL +9.3%) jump after the firm raised its FY12 outlook on revenue to $1.36B-$1.4B, from $1.34-$1.38B, and received an upgrade from Jefferies to Hold. Revenue only jumped 5% Y/Y for the firm, but backlogs increased 29% on new business wins. Comment! [On the Move, Tech]
- Monday, May 23, 2011, 12:49 PM Parexel (PRXL) has been hard hit today, -5.7% after Goldman Sachs downgrades the stock to Sell from Neutral, citing a lack of visibility, margin pressures, and overly aggressive second-half earnings growth projections. Comment! [Healthcare, On the Move, Quick Ideas]
-
- View all 2 replies
-
-
-
Jim Van Meerten
$PRXL - 100% Barchart technical buy signals - 5 new highs and up 8.71% in hte last month - Relative strength Index 68.34% - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
Dividend Sheet
Biggest Players Within Medical Laboratories And Research Industry ++ http://t.co/qNeUzk4 ++ $LH $DGX $CVD $ALR $PPDI $ICLR $IRWD $PRXL - View all 0 replies
-
Justin M. Hall
ZIOP, NBY, EBS, ABT, PRXL, CERN, ACT, CBRX => Notable Developments and Results 12/6/10 => Rx Investors.com => http://bit.ly/c9Kc5C - View all 0 replies
-
Alex B. Gray
Parexel $PRXL reported FY2011 Q1 revenue increased 13.9% to $295.8M and diluted earnings per share increased 42.9% to $0.30. - View all 0 replies
LATEST REPLIES
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 1 replies
-